Cargando…
Tackling Resistance to Cancer Immunotherapy: What Do We Know?
Cancer treatment has evolved tremendously in the last few decades. Immunotherapy has been considered to be the forth pillar in cancer treatment in addition to conventional surgery, radiotherapy, and chemotherapy. Though immunotherapy has resulted in impressive response, it is generally limited to a...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7570938/ https://www.ncbi.nlm.nih.gov/pubmed/32911646 http://dx.doi.org/10.3390/molecules25184096 |
_version_ | 1783597062738149376 |
---|---|
author | Gondhowiardjo, Soehartati A. Handoko, Jayalie, Vito Filbert Apriantoni, Riyan Barata, Andreas Ronald Senoaji, Fajar Utami, IGAA Jayanthi Wulan Maubere, Ferdinand Nuryadi, Endang Giselvania, Angela |
author_facet | Gondhowiardjo, Soehartati A. Handoko, Jayalie, Vito Filbert Apriantoni, Riyan Barata, Andreas Ronald Senoaji, Fajar Utami, IGAA Jayanthi Wulan Maubere, Ferdinand Nuryadi, Endang Giselvania, Angela |
author_sort | Gondhowiardjo, Soehartati A. |
collection | PubMed |
description | Cancer treatment has evolved tremendously in the last few decades. Immunotherapy has been considered to be the forth pillar in cancer treatment in addition to conventional surgery, radiotherapy, and chemotherapy. Though immunotherapy has resulted in impressive response, it is generally limited to a small subset of patients. Understanding the mechanisms of resistance toward cancer immunotherapy may shed new light to counter that resistance. In this review, we highlighted and summarized two major hurdles (recognition and attack) of cancer elimination by the immune system. The mechanisms of failure of some available immunotherapy strategies were also described. Moreover, the significance role of immune compartment for various established cancer treatments were also elucidated in this review. Then, the mechanisms of combinatorial treatment of various conventional cancer treatment with immunotherapy were discussed. Finally, a strategy to improve immune cancer killing by characterizing cancer immune landscape, then devising treatment based on that cancer immune landscape was put forward. |
format | Online Article Text |
id | pubmed-7570938 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75709382020-10-28 Tackling Resistance to Cancer Immunotherapy: What Do We Know? Gondhowiardjo, Soehartati A. Handoko, Jayalie, Vito Filbert Apriantoni, Riyan Barata, Andreas Ronald Senoaji, Fajar Utami, IGAA Jayanthi Wulan Maubere, Ferdinand Nuryadi, Endang Giselvania, Angela Molecules Review Cancer treatment has evolved tremendously in the last few decades. Immunotherapy has been considered to be the forth pillar in cancer treatment in addition to conventional surgery, radiotherapy, and chemotherapy. Though immunotherapy has resulted in impressive response, it is generally limited to a small subset of patients. Understanding the mechanisms of resistance toward cancer immunotherapy may shed new light to counter that resistance. In this review, we highlighted and summarized two major hurdles (recognition and attack) of cancer elimination by the immune system. The mechanisms of failure of some available immunotherapy strategies were also described. Moreover, the significance role of immune compartment for various established cancer treatments were also elucidated in this review. Then, the mechanisms of combinatorial treatment of various conventional cancer treatment with immunotherapy were discussed. Finally, a strategy to improve immune cancer killing by characterizing cancer immune landscape, then devising treatment based on that cancer immune landscape was put forward. MDPI 2020-09-08 /pmc/articles/PMC7570938/ /pubmed/32911646 http://dx.doi.org/10.3390/molecules25184096 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Gondhowiardjo, Soehartati A. Handoko, Jayalie, Vito Filbert Apriantoni, Riyan Barata, Andreas Ronald Senoaji, Fajar Utami, IGAA Jayanthi Wulan Maubere, Ferdinand Nuryadi, Endang Giselvania, Angela Tackling Resistance to Cancer Immunotherapy: What Do We Know? |
title | Tackling Resistance to Cancer Immunotherapy: What Do We Know? |
title_full | Tackling Resistance to Cancer Immunotherapy: What Do We Know? |
title_fullStr | Tackling Resistance to Cancer Immunotherapy: What Do We Know? |
title_full_unstemmed | Tackling Resistance to Cancer Immunotherapy: What Do We Know? |
title_short | Tackling Resistance to Cancer Immunotherapy: What Do We Know? |
title_sort | tackling resistance to cancer immunotherapy: what do we know? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7570938/ https://www.ncbi.nlm.nih.gov/pubmed/32911646 http://dx.doi.org/10.3390/molecules25184096 |
work_keys_str_mv | AT gondhowiardjosoehartatia tacklingresistancetocancerimmunotherapywhatdoweknow AT handoko tacklingresistancetocancerimmunotherapywhatdoweknow AT jayalievitofilbert tacklingresistancetocancerimmunotherapywhatdoweknow AT apriantoniriyan tacklingresistancetocancerimmunotherapywhatdoweknow AT barataandreasronald tacklingresistancetocancerimmunotherapywhatdoweknow AT senoajifajar tacklingresistancetocancerimmunotherapywhatdoweknow AT utamiigaajayanthiwulan tacklingresistancetocancerimmunotherapywhatdoweknow AT maubereferdinand tacklingresistancetocancerimmunotherapywhatdoweknow AT nuryadiendang tacklingresistancetocancerimmunotherapywhatdoweknow AT giselvaniaangela tacklingresistancetocancerimmunotherapywhatdoweknow |